Allan Musinguzi

Completion of isoniazid–rifapentine (3HP) for tuberculosis prevention among people living with HIV: Interim analysis of a hybrid type 3 effectiveness–implementation randomized trial

Fred C. Semitala, Jillian L. Kadota, Allan Musinguzi et al. · PLoS Medicine · 2021 · 28 citations · Full text

Public Health, Infectious Disease Control, Preventive Medicine +17

Protocol for the 3HP Options Trial: a hybrid type 3 implementation-effectiveness randomized trial of delivery strategies for short-course tuberculosis preventive therapy among people living with HIV in Uganda

Jillian L. Kadota, Allan Musinguzi, Juliet Nabunje et al. · Implementation Science · 2020 · 23 citations · Full text

Public Health, Infectious Disease Control, Preventive Medicine +17

Acceptance and completion of rifapentine-based TB preventive therapy (3HP) among people living with HIV (PLHIV) in Kampala, Uganda—patient and health worker perspectives

Fred C. Semitala, Allan Musinguzi, Jackie Ssemata et al. · Implementation Science Communications · 2021 · 21 citations · Full text

Public Health, Health Behavior, Health Sciences +13

Comparison of 3 optimized delivery strategies for completion of isoniazid-rifapentine (3HP) for tuberculosis prevention among people living with HIV in Uganda: A single-center randomized trial

Fred C. Semitala, Jillian L. Kadota, Allan Musinguzi et al. · PLoS Medicine · 2024 · 11 citations · Full text

Public Health, Infectious Disease Control, Preventive Medicine +17